CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Anti–PD-L1 Antibody and/or 17β-Estradiol Treatment Induces Changes in the Gut Microbiome in MC38 Colon Tumor Model
Chin-Hee Song, Nayoung Kim, Ryoung Hee Nam, Soo In Choi, Jae Young Jang, Jina Choi, Ha-Na Lee
Cancer Research and Treatment. 2023;55(3):894-909.   Published online 2023 January 9    DOI: https://doi.org/10.4143/crt.2022.1427

Excel Download

Anti–PD-L1 Antibody and/or 17β-Estradiol Treatment Induces Changes in the Gut Microbiome in MC38 Colon Tumor Model
Cancer Research and Treatment. 2023;55(3):894-909   Crossref logo
Link1 Link2 Link3

Combination treatment with 17β-estradiol and anti-PD-L1 suppresses MC38 tumor growth by reducing PD-L1 expression and enhancing M1 macrophage population in MC38 colon tumor model
Cancer Letters. 2022;543:215780   Crossref logo
Link1 Link2

Biostimulating Gut Microbiome with Bilberry Anthocyanin Combo to Enhance Anti-PD-L1 Efficiency against Murine Colon Cancer
Microorganisms. 2020;8(2):175   Crossref logo
Link1

PD-L1 on lymphatic endothelium inside tumor: a novel predictor for the efficacy of anti-angiogenesis (anlotinib) plus anti-PD-L1 antibody
. 2022;   Crossref logo
Link1 Link2

Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells
Brain Tumor Pathology. 2020;37(2):41-49   Crossref logo
Link1 Link2 Link3

Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and exerts synergistic anti-tumour activity with an anti-PD-1 antibody in colon cancer
Annals of Oncology. 2019;30:v230   Crossref logo
Link1 Link2 Link3

P14.10 Efficacy of Anti-PD-1/PD-L1 Monoclonal Antibody Treatment of Advanced NSCLC on Density and Distribution of Tumor Infiltrating T Cells
Journal of Thoracic Oncology. 2021;16(3):S333   Crossref logo
Link1 Link2

ATG-101, a tetravalent PD-L1×4-1BB bispecific antibody, augments anti-tumor immunity through PD-L1 blockade and PD-L1-directed 4-1BB activation
. 2022;   Crossref logo
Link1 Link2

Comparative efficacy and safety of anti-PD-1/L1 antibody plus anti-VEGF antibody and anti-PD-1/L1 antibody plus VEGFR-targeted tyrosine kinase inhibitor as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a systematic review and network meta- analysis
. 2023;   Crossref logo
Link1 Link2

Epitope characterization of an anti-PD-L1 antibody using orthogonal approaches
Journal of Molecular Recognition. 2015;28(4):269-276   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.